Related Experiment Video
Updated: Aug 12, 2025
09:36
In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats
Published on: March 23, 2022
2.3K
Shedding Light on PARP Inhibitor Response through Functional Imaging
Ying L Liu1,2, Dmitriy Zamarin1,2
1Division of Gynecological Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Summary
Functional PET imaging using a PARP inhibitor (PARPi) analog can identify ovarian cancer patients who will not respond to PARPi therapy. This allows for quicker treatment adjustments, improving patient outcomes and reducing unnecessary toxicity.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Imaging
Background:
- High-grade serous ovarian cancer (HGSOC) treatment often involves poly(ADP-ribose) polymerase inhibitors (PARPi).
- Predicting treatment response to PARPi in HGSOC remains a clinical challenge.
- There is a need for early biomarkers to guide PARPi therapy selection.
Discussion:
- Functional positron emission tomography (PET) imaging with a PARP inhibitor (PARPi) analog shows promise as a predictive biomarker.
- This imaging approach can dynamically assess treatment response early in the course of therapy.
- Identifying non-responders rapidly can prevent exposure to ineffective and toxic treatments.
Key Insights:
- A novel PARPi analog-based PET imaging technique can serve as an early biomarker for PARPi therapy response in HGSOC.
- This method facilitates the rapid identification of patients unlikely to benefit from PARPi treatment.
- Early identification of non-responders allows for timely therapeutic modifications, optimizing patient management.
Outlook:
- This functional PET imaging approach could significantly impact clinical decision-making for PARPi therapy in HGSOC.
- Further validation studies are warranted to integrate this biomarker into standard clinical practice.
- Potential for broader application in other PARPi-treatable malignancies.
